Orgenesis (FRA:45O) Additional Paid-In Capital : €146.88 Mil(As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Orgenesis Additional Paid-In Capital?

Orgenesis's quarterly additional paid-in capital declined from Sep. 2023 (€146.00 Mil) to Dec. 2023 (€143.82 Mil) but then increased from Dec. 2023 (€143.82 Mil) to Mar. 2024 (€146.88 Mil).

Orgenesis's annual additional paid-in capital increased from Dec. 2021 (€129.14 Mil) to Dec. 2022 (€141.94 Mil) and increased from Dec. 2022 (€141.94 Mil) to Dec. 2023 (€143.82 Mil).

Orgenesis Additional Paid-In Capital Historical Data

The historical data trend for Orgenesis's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orgenesis Additional Paid-In Capital Chart

Orgenesis Annual Data

Trend

Nov14

Nov15

Nov16

Nov17

Nov18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

85.22

115.41

129.14

141.94

143.82

Orgenesis Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															144.48	142.83	146.00	143.82	146.88

Orgenesis Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Orgenesis Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Orgenesis's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Orgenesis (FRA:45O) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orgenesis Inc (FRA:45O) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

ORGS:USA

Address

20271 Goldenrod Lane, Germantown, MD, USA, 20876

Website

https://www.orgenesis.com

Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Morgenesis and Therapies.

Orgenesis (FRA:45O) Headlines

No Headlines